Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders, with a unique understanding of the CNS market. Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships, and acquisitions. The company has c.1,000 employees and develops and commercialises CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East, one in Australia, and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira. Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain. To learn more about Neuraxpharm, please visit https://www.neuraxpharm.com
| Website | http://www.neuraxpharm.com |
| Revenue | $546.4 million |
| Employees | 914 (592 on RocketReach) |
| Founded | 1985 |
| Phone | +49 2173 10600 |
| Technologies |
JavaScript
,
HTML
,
PHP
+26 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Pharmaceutical, Health Care |
| Keywords | Central Nervous System, Psychiatric Disorders, Neurological Disorders, Neurological Drugs, Brain Health, Mental Health, Pharmaceutical Drugs, Prescription Drugs, Cognitive Disorders, Neurodegenerative Diseases, Movement Disorders, Epilepsy Treatment, Pain Management, Sleep Disorders, Anxiety Treatment, Depression Treatment |
| Competitors | Roche, Amgen, Teva Pharmaceuticals, Novartis, Fresenius Kabi, Sandoz, SUN PHARMA, Aurobindo Pharma, Mylan Belgium +47 more (view full list) |
Looking for a particular Neuraxpharm employee's phone or email?
The Neuraxpharm annual revenue was $546.4 million in 2026.
Jörg Dierks is the CEO of Neuraxpharm.
592 people are employed at Neuraxpharm.